Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Proteomics International Laboratories Ltd. ( (AU:PIQ) ) has provided an announcement.
Proteomics International Laboratories reported a weak first half for the six months to 31 December 2025, with operating and other activity revenues falling 30% to $357,000 and total income including grants and other revenue declining 10% to $868,749. The company’s net loss attributable to members widened by 34% to $6.03 million, though net tangible asset backing per share improved to 4.4 cents from 4.0 cents, signalling continued balance sheet support despite mounting losses and the absence of any dividend.
The most recent analyst rating on (AU:PIQ) stock is a Hold with a A$0.38 price target. To see the full list of analyst forecasts on Proteomics International Laboratories Ltd. stock, see the AU:PIQ Stock Forecast page.
More about Proteomics International Laboratories Ltd.
Proteomics International Laboratories Ltd, based in Perth, Western Australia and listed on the ASX as PIQ, is a medical technology company focused on precision diagnostics and bioanalytical services. Operating in the proteomics field, it develops and applies protein-based analytical tools aimed at improving disease treatment and patient outcomes across healthcare markets.
Average Trading Volume: 593,363
Technical Sentiment Signal: Sell
Current Market Cap: A$62.77M
For an in-depth examination of PIQ stock, go to TipRanks’ Overview page.